Amiloride hydrochloride dihydrate
CAT:
804-HY-B0285B-01
Size:
10 mM / 1 mL
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Amiloride hydrochloride dihydrate
- CAS Number: 17440-83-4
- UNSPSC Description: Amiloride hydrochloride dihydrate (MK-870 hydrochloride dihydrate) is an inhibitor of both epithelial sodium channel (ENaC[1]) and urokinase-type plasminogen activator receptor (uTPA[2]). Amiloride hydrochloride dihydrate is a blocker of polycystin-2 (PC2; TRPP2[3]) channel.
- Target Antigen: Apoptosis; Sodium Channel; TRP Channel
- Type: Reference compound
- Related Pathways: Apoptosis;Membrane Transporter/Ion Channel;Neuronal Signaling
- Applications: Neuroscience-Neurodegeneration
- Field of Research: Metabolic Disease; Cardiovascular Disease
- Assay Protocol: https://www.medchemexpress.com/Amiloride_hydrochloride_dihydrate.html
- Purity: 99.85
- Solubility: DMSO : 83.33 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 2 mg/mL (ultrasonic)
- Smiles: O=C(C1=NC(Cl)=C(N)N=C1N)NC(N)=N.[H]Cl.O.O
- Molecular Weight: 302.12
- References & Citations: [1]Miller RL, et al. Blockade of ENaCs by amiloride induces c-Fos activation of the area postrema. Brain Res. 2015 Mar 19;1601:40-51.|[2]Xu LB, et al. Amiloride, a urokinase-type plasminogen activator receptor (uTPA) inhibitor, reduces proteinurea in podocytes. Genet Mol Res. 2015 Aug 14;14(3):9518-29.|[3]Giamarchi A, et al. A polycystin-2 (TRPP2) dimerization domain essential for the function of heteromeric polycystin complexes. EMBO J. 2010 Apr 7;29(7):1176-91.Transl Res. 2023 Sep 5;S1931-5244(23)00143-3.|ACS Nano. 2023 Apr 14.|Adv Funct Mater. 2024 Oct 31.|Adv Sci (Weinh). 2023 Dec 14:e2307880.|Am J Transl Res. 2021 Jul 15;13(7):7538-7555.|Cell Commun Signal. 2023 May 4;21(1):99.|Cell Metab. 2022 Dec 6;34(12):2018-2035.e8.|Cell Physiol Biochem. 2018;51(6):2564-2574. |Commun Biol. 2022 Nov 14;5(1):1248.|Environ Sci Technol. 2021 Feb 11.|Int J Biol Macromol. 2024 Aug 5;277(Pt 3):134517.|J Am Chem Soc. 2018 Dec 12;140(49):17234-17240.|J Control Release. 2024 Oct 26:S0168-3659(24)00725-9.|J Leukoc Biol. 2024 Jul 16:qiae159.|J Nanobiotechnology. 2020 Jan 31;18(1):26.|J Pharmaceut Biomed. 2020, 113870.|Microb Pathog. 2019 Jul 18:103638. |Nanotechnology. 2018 Feb 23;29(8):085101.|Nat Biomed Eng. 2024 Sep 13.|Nat Nanotechnol. 2024 Aug 26.|Small Methods. 2020 Dec 18.|Theranostics. 2019 May 31;9(13):3732-3753.|Acta Pharm Sin B. 2024 Jul 27.|Biomaterials. 2022 May;284:121529.|Br J Pharmacol. 2020 Aug;177(15):3473-3488. |Cell Mol Immunol. 2024 Jun 13.|Cell Rep. 2022 May 31;39(9):110880.|Food Chem. 2024 Sep 8;463(Pt 1):141196.|Int J Biol Macromol. 14 March 2022.|iScience. 19 October 2022, 105403.|J Ethnopharmacol. 2022 Mar 5;115171.|J Neuroinflammation. 2022 Feb 22;19(1):53.|Sci Total Environ. 2021, 146523.|Theranostics. 2020 May 17;10(15):6581-6598.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched